Pharming's C1 inhibitor granted IND for kidney transplants
This article was originally published in Scrip
Executive Summary
Pharming's recombinant human C1 inhibitor product has been granted an investigational new drug (IND) application by the US FDA for preventing antibody-mediated rejection in kidney transplantation. The Netherlands-based biotech is to conduct clinical trials examining the product's impact on inflammatory damage and kidney graft loss, compared with current treatment. Pharming has also developed its recombinant human C1 inhibitor as Rhucin for hereditary angioedema. Rhucin has been received a negative opinion from the EU's CHMP, but the product is being developed with a view to US filing.
You may also be interested in...
Amgen reveals more details of denosumab's fracture benefit
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Targacept/AstraZeneca Alzheimer's hope fails in Phase II
Targacept and AstraZeneca's investigational Alzheimer's disease drug ispronicline has failed to show improvement over placebo in a Phase IIb study.
Gilead must conduct another study of cystic fibrosis drug, FDA says
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.